2/11/2013

More data is needed on cardiovascular risks before Novo Nordisk's long-acting insulin Tresiba can be approved by the FDA. Chief Scientific Officer Mads Thomsen said the company could meet with the FDA in the coming days to discuss possible next steps.

Related Summaries